Table 1 Characteristics of patients with refractory germ cell tumors enrolled in the sutent phase 2 study and outcomes at presentation
Pt # | Race | Age ++ | PS | Primary mass | Pathology- Components | Prior Therapies | AFP ng/ml (0–5.0) | B-HCG mIU/ml (0–1) | LDHIU/L (313–618) |
|---|---|---|---|---|---|---|---|---|---|
1 | AA | 17 | 0 | Testis | Seminoma;Embryonal, Choriocarcinoma, Immature teratoma, Mature teratoma. | R orchiectomy, BEP × 4, RPLND,TIP, Gem + Etoposide, Avastin + Gem, Avatin, Taxol, Gem, | 18495.6 | <1.0 | 2386 |
2 | Asian | 20 | 0 | Mediastinum | Yolk sac tumor, Endodermal Sinus Tumor. | BEP × 3, TIP × 2, Surgery- multiple, ACE × 2 | 2087.9 | <1.0 | 419 |
3 | White | 36 | 1 | Testis | Embryonal Carcinoma (80%) and yolk sac tumor (20%) | R orchiectomy, BEP × 3, RPLND,TIP × 4, XRT- T10 -L2 , Cisplatin + Epirubicin × 4, XRT to R chest wall, WBRT, Oxaliplatin + Gem, × 4, Oxaliplatin × 8, Gem × 3, etoposide × 3 | 108.9 | <1.1 | 524 |
4 | White | 19 | 1 | Retro-peritoneal mass | Teratoma and Choriocarcinoma | BEP × 4, TIP × 1, VIP × 5, HD-SCT with carboplatin + etoposide, RPLND, | 1.1 | 227865.8 | 794 |
5 | White | 29 and 52* | 1 | Testis | Embryonal Carcinoma (80%) and yolk sac tumor (20%) | R orchiectomy, 20 yrs later BEP × 3, EP × 1, RPLND, TIP × 2, ACE × 1 | 235.5 | 19.8 | 635 |